NCT00016289View on ClinicalTrials.gov

Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2001

Primary Completion Date

July 31, 2007

Conditions
Primary Peritoneal Cavity CancerRecurrent Ovarian Epithelial Cancer
Interventions
BIOLOGICAL

recombinant interleukin-12

Given intraperitoneally

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00016289 - Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter